Cemiplimab-associated pneumonitis/interstitial lung disease reporting in cervical cancer: a FAERS active-comparator study with JADER validation

Cervical cancer remains a formidable global health challenge, claiming hundreds of thousands of lives each year, particularly in regions where access to screening and advanced treatment is limited. For patients whose disease returns or spreads after standard chemotherapy, doctors have turned to a class of drugs known as immune checkpoint inhibitors. These medicines work by removing the biological "brakes" that cancer cells use to hide from the body's own immune system, effectively waking up the immune system to hunt down the tumor. While these drugs have transformed the treatment landscape, they come with a unique set of risks. Because they rev up the immune system, they can sometimes cause it to attack healthy organs, leading to side effects known as immune-related adverse events. Among these, inflammation of the lungs, a condition called pneumonitis or interstitial lung disease, is a serious concern. It can be difficult to distinguish from other lung problems common in cancer patients, such as infections or the spread of cancer itself, making it a critical area for close monitoring.

Researchers recently turned to a massive, global database of spontaneous medical reports to investigate how one specific immune drug, cemiplimab, compares to another well-known drug in the same family, pembrolizumab, when used for cervical cancer. The study focused on a specific question: does cemiplimab trigger lung inflammation more frequently than its counterpart? By analyzing millions of reports submitted to the U.S. Food and Drug Administration's Adverse Event Reporting System, the team identified 201 cases involving cemiplimab and over 2,000 involving pembrolizumab, all linked to cervical cancer. They then looked for patterns in how often doctors reported lung problems for each drug. The analysis revealed a distinct signal: reports of pneumonitis or interstitial lung disease appeared significantly more often with cemiplimab than with pembrolizumab. Specifically, lung issues were noted in roughly 11 percent of the cemiplimab reports, compared to just over 3 percent for pembrolizumab. This difference was not a fluke of the data; it held true even when the researchers adjusted for how the drugs were prescribed or who reported the events.

However, the story behind these numbers is nuanced. The researchers discovered that the strength of this signal was heavily influenced by where the reports came from. A large portion of the cemiplimab reports originated from Japan, where the drug has been approved for this specific use, whereas the United States has not yet approved cemiplimab for cervical cancer. When the researchers looked only at reports from Japan, the difference in lung problems between the two drugs was even more pronounced. When they removed the Japanese reports from the analysis, the gap between the two drugs narrowed considerably, suggesting that local reporting habits, regulatory environments, or clinical practices might play a role alongside biological factors. To confirm this pattern, the team cross-referenced their findings with an independent database from Japan, which showed a similar trend of higher lung-related reporting for cemiplimab.

Crucially, the study found that this difference was specific to the lungs. When the researchers examined other serious side effects, such as heart problems, liver issues, or skin reactions, the two drugs performed similarly, with no clear winner in terms of safety. Furthermore, the overall rate of severe outcomes, including hospitalization and death, was comparable between the two groups. This suggests that cemiplimab is not broadly more toxic than pembrolizumab, but rather carries a specific, heightened risk for lung inflammation that warrants attention. The researchers emphasized that these findings are signals from a reporting system, not a final count of how many people get sick, as the database lacks information on the total number of patients treated. Nevertheless, the consistency of the lung signal across different analyses and databases offers a clear message for clinicians: patients receiving cemiplimab for cervical cancer should be monitored with extra care for signs of lung inflammation, as this appears to be a distinct vulnerability compared to other drugs in its class.